Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations

International Journal of Cancer

Volumn 68, Issue 4, 1996, Pages 501-505

  Kawasaki, Takashi ^a   Tomita, Yoshihiko ^a   Bilim, Vladimir ^a   Takeda, Masayuki ^a   Takahashi, Kota ^a   Kumanishi, Toshiro ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; MITOMYCIN C; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DNA DAMAGE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

APOPTOSIS; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA; DNA DAMAGE; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MITOMYCIN; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0029846455     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7     Document Type: Article

References (24)

1. BHATIA, K., FAN, S., SPANGLER, G., WEINTRAUB, M., O'CONNOR, P.M., JUDDE, J.-G. and MAGRATH, I., A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res., 55, 1431-1435 (1995).
2. CHEN, J., JACKSON, P.K., KIRSCHNER, M.W. and DUTTA, A., Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (Lond.), 374, 386-388 (1995).
3. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174 (1994).
4. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
5. EL-DEIRY, W.S., TOKINO, T., WALDMAN, T., OLINER, J.D., VELCULESCU, V.E., BURRELL, M., HILL, D.E., HEALY, E., REES, J.L., HAMILTON, S.R., KINZLER, K.W. and VOGELSTEIN, B., Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919 (1995).
6. GAO, X., CHEN, Y.Q., Wu, N., GRIGNON, D.J., SAKR, W., PORTER, A.T. and HONN, K.V., Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene, 11, 1395-1398 (1995).
7. 1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
8. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C.C.,p53 mutations in human cancers. Science, 253, 49-53 (1991).
9. KASTAN, M.B., ONYEKWERE, O., SIDRANSKY, D., VOGELSTEIN, B. and CRAIG, R.W., Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311 (1991).
10. KAWASAKI, T., TOMITA, Y., WATANABE, R., TANIKAWA, T., KUMANISHI, T. and SATO, S., mRNA and protein expression of p53 mutations in human bladder-cancer cell lines. Cancer Lett., 82, 113-121 (1994).
11. LI, Y.J., LAURENT-PUIG, P., SALMON, R.J., THOMAS, G. and HAMELIN, R., Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene, 10, 599-601 (1995).
12. Luo, Y., HURWITZ, J. and MASSAGUE, J., Cell-cycle inhibition by independent CDK- and PCNA-binding domains in p21Cip1. Nature (Lond.), 375, 159-161 (1995).
13. MARTINEZ-PINEIRO, J.A., MARTIN, M.G., AROCENA, F., FLORES, N., RONCERO, C.R., PORTILLO, J.A., ESCUDERO, A., CRUZ, F.J. and ISORNA, S., Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional-cell carcinoma of the bladder: a prospective randomized phase-III study. J. Urol., 153, 964-973 (1995).
14. MOSMANN, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
15. SHAW, P., BOVEY, R., TARDY, S., SCHLI, R., JORDAT, B. and COSTA, J., Induction of apoptosis by wild-type p53 in a human colon-tumorderived cell line. Proc. not. Acad. Sci. (Wash.), 89, 4495-4499 (1992).
16. SHIOHARA, M., EL-DEIRY, W.S., WADA, M., NAKAMAKI, T., TAKEUCHI, S., YANG, R., CHEN, D.L., VOGELSTEIN, B. and KOEFFLER, H.P., Absence of WAF1 mutations in a variety of human malignancies. Blood, 84, 3781-3784 (1994).
17. SIDRANSKY, D., ESCHENBACH, A.V., TSAI, Y.C., JONES, P., SUMMER-HAYES, I., MARSHALL, F., PAUL, M., GREEN, P., HAMILTON, S.R., FROST, P. and VOGELSTEIN, B., Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252, 706-709 (1991).
18. SOUSSI, T., DE FROMENTEL, C.C. and MAY, P., Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5, 945-952 (1990).
19. STEINMAN, R.A., HOFFMAN, B., IRO, A., GUILLOUF, C., LIEBERMANN, D.A. and EL-HOUSEINI, M.E., Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene, 9, 3389-3396 (1994).
20. TOMITA, Y., BILIM, V., KAWASAKI, T., KOTA, T., ISMAIL, O., MAGNUSSON, K. and WIMAN, K.G., Frequent expression of bcl-2 in renal-cell carcinomas carrying wild-type p53. Int. J. Cancer, 66, 322-325 (1996).
21. WAGA, S., HANNON, G.J., BEACH, D. and STILLMAN, B., The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369, 574-578 (1994).
22. 1 cell-cycle arrest and transactivation of WAF1 and bax. Cell Growth Differ., 6, 1071-1075 (1995).
23. WATANABE, H., FUKUCHI, K., TAKAGI, Y., TOMOYASU, S., TSURUOKA, N. and GOMI, K., Molecular analysis of the Cip1/Wafl(p 21) gene in diverse types of human tumors. Biochim. biophys. Acta, 1263, 275-280 (1995).
24. XIONG, Y., HANNON, G.J., ZHANG, H., CASSO, D., KOBAYASHI, R. and BEACH, D., p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366, 701-704 (1993).